PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants. Preliminary assessment of the immunological effects of CYT107 in 8 evaluable patients demonstrates a median increase in CD4 T cells exhibiting a naïve or central memory phenotype of 69% over baseline, and a median increase in CD8 T cells exhibiting a naïve or effector memory phenotype of 94% over baseline.
